| Epidermal growth factor receptor tyrosine kinase inhibitors for non–small-cell lung cancer patients with leptomeningeal carcinomatosis BC Liao, JH Lee, CC Lin, YF Chen, CH Chang, CC Ho, JY Shih, CJ Yu, ... Journal of Thoracic Oncology 10 (12), 1754-1761, 2015 | 183 | 2015 |
| Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer BC Liao, CC Lin, JCH Yang Current opinion in oncology 27 (2), 94-101, 2015 | 154 | 2015 |
| Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer CC Hsu, BC Liao, WY Liao, A Markovets, D Stetson, K Thress, JCH Yang Journal of Thoracic Oncology 15 (1), 50-61, 2020 | 64 | 2020 |
| Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma … CY Yang, WY Liao, CC Ho, KY Chen, TH Tsai, CL Hsu, KY Su, YL Chang, ... European journal of cancer 124, 110-122, 2020 | 64 | 2020 |
| Lung cancer in Republic of China YH Luo, CH Chiu, CHS Kuo, TY Chou, YC Yeh, HS Hsu, SH Yen, YH Wu, ... Journal of Thoracic Oncology 16 (4), 519-527, 2021 | 57 | 2021 |
| Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: real-world data in Taiwan SY Lin, CY Yang, BC Liao, CC Ho, WY Liao, KY Chen, TH Tsai, CL Hsu, ... Journal of Cancer 9 (10), 1813, 2018 | 56 | 2018 |
| Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors BC Liao, CC Lin, JH Lee, JCH Yang Journal of biomedical science 23, 1-10, 2016 | 51 | 2016 |
| Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy BC Liao, CC Lin, JH Lee, JCH Yang Lung Cancer 110, 7-13, 2017 | 46 | 2017 |
| Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): a phase II study with biomarker analysis HF Kao, BC Liao, YL Huang, HC Huang, CN Chen, TC Chen, YJ Hong, ... Clinical Cancer Research 28 (8), 1560-1571, 2022 | 42 | 2022 |
| Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients BC Liao, S Griesing, JCH Yang Therapeutic advances in medical oncology 11, 1758835919890286, 2019 | 38 | 2019 |
| Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy BC Liao, CC Lin, JY Shih, JCH Yang Therapeutic advances in medical oncology 7 (5), 274-290, 2015 | 33 | 2015 |
| Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma BC Liao, YY Shao, HM Chen, WY Shau, ZZ Lin, RN Kuo, CL Lai, KH Chen, ... Clinical Lung Cancer 16 (2), 137-143, 2015 | 24 | 2015 |
| Novel EGFR inhibitors in non-small cell lung cancer: current status of afatinib BC Liao, CC Lin, JCH Yang Current oncology reports 19, 1-9, 2017 | 23 | 2017 |
| Association of programmed death‐ligand 1 expression with fusion variants and clinical outcomes in patients with anaplastic lymphoma kinase‐positive lung adenocarcinoma … CY Yang, WY Liao, CC Ho, KY Chen, TH Tsai, CL Hsu, YN Liu, KY Su, ... The oncologist 25 (8), 702-711, 2020 | 21 | 2020 |
| First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments BC Liao, CC Lin, JCH Yang Drugs 73, 357-369, 2013 | 21 | 2013 |
| CD73 is regulated by the EGFR-ERK signaling pathway in non-small cell lung cancer S Griesing, BC Liao, JCH Yang Anticancer research 41 (3), 1231-1242, 2021 | 18 | 2021 |
| Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors BC Liao, YY Bai, JH Lee, CC Lin, SY Lin, YF Lee, CC Ho, JY Shih, ... Journal of the Formosan Medical Association 117 (4), 326-331, 2018 | 12 | 2018 |
| 266O Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939 HF Kao, MK Ang, QS Ng, DSW Tan, W Tan, T Rajasekaran, A Jain, ... Annals of Oncology 31, S1347, 2020 | 11 | 2020 |
| Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice YH Liang, YY Shao, BC Liao, HS Lee, JCH Yang, HM Chen, CJ Chiang, ... Journal of Cancer 7 (11), 1515, 2016 | 11 | 2016 |
| Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma DWT Lim, HF Kao, L Suteja, CH Li, HS Quah, DSW Tan, SH Tan, EH Tan, ... Nature Communications 14 (1), 2781, 2023 | 8 | 2023 |
